AI assistant
AMGEN INC — Director's Dealing 2025
Mar 6, 2025
29819_dirs_2025-03-05_8d9a7c95-c953-4e93-a312-b799a7c9e280.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AMGEN INC (AMGN)
CIK: 0000318154
Period of Report: 2025-03-03
Reporting Person: Grygiel Nancy A. (SVP & CCO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-03-03 | Common Stock | A | 1503 | — | Acquired | 8713 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 102.2192 | Indirect |
Footnotes
F1: These shares include 114 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
F2: These are shares acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing.